Artiva Biotherapeutics Inc
ARTV2.880USD
+0.500+21.01%
Handelsschluss 09/19, 16:00（ET）Kurse um 15 Minuten verzögert
70.25MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Artiva Biotherapeutics Inc Unternehmen
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. The Company's product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as LN, RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, SLE and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
Unternehmensinformationen
BörsenkürzelARTV
Name des UnternehmensArtiva Biotherapeutics Inc
IPO-datumJul 19, 2024
CEODr. Fred Aslan, M.D.
Anzahl der mitarbeiter89
WertpapierartOrdinary Share
GeschäftsjahresendeJul 19
Addresse5505 Morehouse Drive
StadtSAN DIEGO
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl92121
Telefon18582674467
Websitehttps://www.artivabio.com/
BörsenkürzelARTV
IPO-datumJul 19, 2024
CEODr. Fred Aslan, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
40.97K
-3.85%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
2.41K
-35.76%
Ms. Jennifer Bush
Ms. Jennifer Bush
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
--
--
Dr. Laura Stoppel, Ph.D.
Dr. Laura Stoppel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Independent Director
Independent Director
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Dr. Alison Moore, Ph.D.
Dr. Alison Moore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Christopher P. Horan
Mr. Christopher P. Horan
Chief Technical Operations Officer
Chief Technical Operations Officer
--
--
Dr. Brian Daniels, M.D.
Dr. Brian Daniels, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
40.97K
-3.85%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
2.41K
-35.76%
Ms. Jennifer Bush
Ms. Jennifer Bush
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
--
--
Dr. Laura Stoppel, Ph.D.
Dr. Laura Stoppel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Independent Director
Independent Director
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Umsatzaufteilung
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q1
FY2022
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Aug 19
Aktualisiert: Tue, Aug 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
40.34%
GC Biopharma Corp
18.70%
5AM Ventures
9.63%
VR Adviser, LLC
6.59%
VenBio Partners LLC
4.70%
Andere
20.03%
Aktionäre
Aktionäre
Anteil
RA Capital Management, LP
40.34%
GC Biopharma Corp
18.70%
5AM Ventures
9.63%
VR Adviser, LLC
6.59%
VenBio Partners LLC
4.70%
Andere
20.03%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
57.76%
Corporation
18.70%
Private Equity
4.70%
Investment Advisor/Hedge Fund
4.51%
Hedge Fund
4.08%
Investment Advisor
4.06%
Individual Investor
1.15%
Research Firm
0.82%
Andere
4.21%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
104
25.61M
104.85%
+2.90M
2025Q1
101
26.68M
109.52%
+4.03M
2024Q4
89
26.90M
110.75%
+5.25M
2024Q3
74
26.42M
108.79%
+10.37M
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
RA Capital Management, LP
9.85M
40.44%
--
--
Mar 31, 2025
GC Biopharma Corp
4.57M
18.75%
+4.57M
--
Jul 22, 2024
5AM Ventures
2.35M
9.66%
--
--
Mar 31, 2025
VR Adviser, LLC
1.61M
6.61%
--
--
Mar 31, 2025
VenBio Partners LLC
1.20M
4.92%
-321.00K
-21.12%
Mar 31, 2025
Franklin Advisers, Inc.
520.33K
2.14%
+26.00
+0.00%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.16M
4.74%
+189.32K
+19.60%
Mar 31, 2025
Samsara BioCapital, LLC
291.67K
1.2%
--
--
Mar 31, 2025
Woodline Partners LP
283.12K
1.16%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
